** daily **
** weekly **
** daily **
** monthly **
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc., and a product candidate in Phase I development for schizophrenia in collaboration with Meiji Seika Pharma Co., Ltd. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.
Address
3911 Sorrento Valley Blvd
SAN DIEGO, CA 92121
United States
SAN DIEGO, CA 92121
United States
Website links
www.acadia-pharm.comKey stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -2013.53% | -424.88% |
| Operating margin | -2030.38% | -425.64% |
| EBITD margin | - | -423.42% |
| Return on average assets | -23.50% | -29.64% |
| Return on average equity | -27.90% | -38.49% |
| Employees | 26 |
No comments:
Post a Comment